Axsome Thera (AXSM) Stock Price, Quote & News

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 332 3241

Fax: 212 320 0245

Website: www.axsome.com

Address:

One World Trade Center, 29th Floor, New York, United States

RickSanders9 Apr. 4 at 8:36 PM

$AXSM I just saw director competitor & Acadia CEO Catherine Adams on CNBC Squawk Box. A quick search shows that she was on Bloomberg in January, Business Week in January, Bloomberg again in March, and now CNBC. Axsome needs to do better with Herriot Tabuteau's generational and truly unprecedented story & leverage it into exposure!

1 · Reply

Vakeshka Apr. 4 at 6:20 AM

$AXSM a new Auvelity review. Che... April 2, 2026 "Reading all the other reviews made me want to cry with joy with so many people saying the same words and feelings I have felt. I have been on Auvelity now for about 2 months. When I was first prescribed it, I just thought, 'Great, another antidepressant medication.' I have been on and off meds since I was 13. Let me tell you, Auvelity kicked my behind, in a fantastic way. I went through some major life changes the past 3 years, and I suppose I quit processing things, and I had a complete mental breakdown this past year. It was day 2 of taking Auvelity, and I could feel a cloud-like fog moving from the back of my head to the front, and it was kind of a tingly feeling too. Then all of a sudden, I could start processing information again. I am a visual thinker, and I could literally see the words rushing in.... I have a more stable feeling now, but the first month I would feel it like that. I feel so good."

0 · Reply

quickaspeter Apr. 3 at 4:37 PM

$AXSM Let’s go!!! 💥🚀💰💰

0 · Reply

quickaspeter Apr. 3 at 4:36 PM

$AXSM Another potential beauty!!

1 · Reply

11thestate Apr. 3 at 1:26 PM

Missed the $AXSM deadline? You might not be out of options. Axsome reached a $7.75M settlement with investors who were affected by misleading statements about regulatory risks of the AXS-07. If you invested between May 2021 and Apr 2022, late claims are still being considered, but that window won't stay open forever. Check if you're eligible 👉 https://11th.com/cases/axsome-investor-settlement

0 · Reply

Bio_investor_ Apr. 2 at 6:08 PM

$AXSM May be approval within next 2 weeks because of BTD designation.

0 · Reply

jlfromli Apr. 2 at 5:48 PM

$AXSM They need to come Out with a bi-polar Drug. Because this symbol Is.

2 · Reply

chuckL4 Apr. 2 at 5:19 PM

$AXSM From Gemini: Summary for Investors: If you are tracking a drug with Breakthrough status, the PDUFA date should be treated as the absolute latest possible date for a decision. It is common for these approvals to land weeks—or even months—early because the FDA has already been looking at the data for a year or more.

0 · Reply

RiskScalper Apr. 2 at 4:07 PM

$AXSM one of those biotechs that can run hard if momentum returns

0 · Reply

chuckL4 Apr. 2 at 3:18 PM

$AXSM Feels to me if approval is received on April 30 for Alzheimer Agitation, the entire narrative for AXSM will change. This will give us 2 blockbuster products with Auvelity, several other mid level products with Sunosi and Symbravo, and a very rich pipeline with foreign rights still owned by AXSM for these products. This should be squarely in big pharma's crosshairs as they look to replace their patent cliff. Altho approval is not a certainty for Alzheimers, given the Breakthrough designation, favorable studies, lack of any clean alternative products to treat the agitation, and no comments from the FDA thus far - I like our odds.

1 · Reply

Axsome Therapeutics, Inc. (AXSM) Presents at The Citizens Life Sciences Conference 2026 Transcript

Mar 10, 2026, 7:40 PM EDT - 25 days ago

Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript

Feb 25, 2026, 7:00 AM EST - 5 weeks ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Feb 23, 2026, 12:25 PM EST - 5 weeks ago

Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued

Feb 23, 2026, 11:34 AM EST - 5 weeks ago

Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript

Feb 23, 2026, 7:00 AM EST - 5 weeks ago

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 17, 2026, 7:00 AM EST - 6 weeks ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

Jan 27, 2026, 7:00 AM EST - 2 months ago

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

Jan 24, 2026, 6:38 AM EST - 2 months ago

Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline

Jan 12, 2026, 4:20 PM EST - 2 months ago

MoneyShow's Best Investment Ideas For 2026: Part 2

BDX BRO BX CALM

Jan 12, 2026, 7:00 AM EST - 2 months ago

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

Dec 31, 2025, 10:30 AM EST - 3 months ago

FDA Fast-Tracks Axsome's Alzheimer's Agitation Drug, Stock Soars

Dec 31, 2025, 6:55 AM EST - 3 months ago

Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission

Dec 4, 2025, 6:18 PM EST - 4 months ago

Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 6, 2025, 7:00 AM EST - 5 months ago

Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy

Nov 6, 2025, 7:00 AM EST - 5 months ago

Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics

FBIO

Nov 5, 2025, 3:12 PM EST - 5 months ago

Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer

Nov 3, 2025, 2:46 PM EST - 5 months ago

Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript

Oct 24, 2025, 11:20 AM EDT - 5 months ago

Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Oct 10, 2025, 4:07 AM EDT - 6 months ago

Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating

Oct 9, 2025, 7:00 AM EDT - 6 months ago

Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community

Oct 7, 2025, 7:00 AM EDT - 6 months ago

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

Sep 18, 2025, 1:53 AM EDT - 7 months ago

Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Sep 8, 2025, 5:49 PM EDT - 7 months ago

Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 5, 2025, 1:40 PM EDT - 8 months ago

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Aug 4, 2025, 2:50 PM EDT - 8 months ago

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 8 months ago

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 1:46 PM EDT - 9 months ago

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Jul 21, 2025, 7:30 AM EDT - 9 months ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Jul 9, 2025, 7:00 AM EDT - 9 months ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Jul 7, 2025, 7:00 AM EDT - 9 months ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Jun 20, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Jun 11, 2025, 7:00 AM EDT - 10 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

May 27, 2025, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 13, 2025, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 6, 2025, 12:48 PM EDT - 11 months ago

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 5, 2025, 11:44 AM EDT - 11 months ago

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:41 AM EDT - 11 months ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Apr 8, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Apr 4, 2025, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Apr 1, 2025, 7:18 AM EDT - 1 year ago

Axsome's depression treatment fails to meet main goal of late-stage study

Mar 25, 2025, 7:13 AM EDT - 1 year ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 21, 2025, 11:36 AM EDT - 1 year ago

Axsome: The Alzheimer's Agitation Program For AXS-05

Feb 24, 2025, 1:34 PM EST - 1 year ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Feb 20, 2025, 8:15 AM EST - 1 year ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 18, 2025, 11:12 AM EST - 1 year ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:20 PM EST - 1 year ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

TEVA

RickSanders9 Apr. 4 at 8:36 PM

1 · Reply

Vakeshka Apr. 4 at 6:20 AM

0 · Reply

quickaspeter Apr. 3 at 4:37 PM

$AXSM Let’s go!!! 💥🚀💰💰

0 · Reply

quickaspeter Apr. 3 at 4:36 PM

$AXSM Another potential beauty!!

1 · Reply

11thestate Apr. 3 at 1:26 PM

0 · Reply

Bio_investor_ Apr. 2 at 6:08 PM

$AXSM May be approval within next 2 weeks because of BTD designation.

0 · Reply

jlfromli Apr. 2 at 5:48 PM

$AXSM They need to come Out with a bi-polar Drug. Because this symbol Is.

2 · Reply

chuckL4 Apr. 2 at 5:19 PM

0 · Reply

RiskScalper Apr. 2 at 4:07 PM

$AXSM one of those biotechs that can run hard if momentum returns

0 · Reply

chuckL4 Apr. 2 at 3:18 PM

1 · Reply

Vakeshka Apr. 2 at 10:36 AM

$AXSM a new Auvelity review. Sco... March 30, 2026 "OCD OCD OCD! I have dealt with what I thought was the worst “Pure O” OCD in the history of all of mankind. I am 31, and it started when I was 6 years old. Over the course of my life, I have gone through a tremendously complex amount of “trauma” experiences literally because of my OCD. OCD has been, for my whole life, like an abusing, torturing, and debilitating condition in my mind. I tried everything known to help. Every SSRI, ketamine, TMS, mushrooms. I tried augmentation with antipsychotics. I tried stimulant and non-stimulant medications to calm my mind. Nothing truly helped more than taking the edge off. I am on day 6 of this medication, and my OCD is literally gone. It is gone! I am in disbelief that this is truly real and this is happening. My thoughts are because of how this drug regulates glutamate, which is overactive in OCD. How the hell could doctors and psychiatrists be in 2026 and not understand this? Anyway, praise God!"

0 · Reply

Mike826_1999 Apr. 1 at 11:42 PM

$AXSM Axsome likely does not see Balipodect as a failure. The Phase 2 study missed its goal, but it showed promising signs. The effect just was not strong enough in that trial setup. A big issue was how the study was run. Balipodect was tested at one dose, had a high placebo response, and no active comparison. That makes it harder to show a clear benefit. Axsome likely thinks it may have been underdosed or tested in the wrong patients. It was also tested as a standalone drug. Based on how it works, Balipodect may do better as an add on to existing treatments or in targeting specific symptoms like cognitive or negative symptoms. The safety profile is another reason they pursued it. Balipodect was well tolerated and did not show the common side effects seen with other drugs, which gives more flexibility. They're betting the issue was the testing, not the drug itself. If improved trial design, dosing, and patient selection, they believe they can get better results. https://www.sciencedirect.com/science/article/abs/pii/S0920996418305401?via%3Dihub

0 · Reply

Crimson_Phoenix Apr. 1 at 6:42 PM

$AXSM Jefferies Reiterates Buy Rating, $245 price. https://www.investing.com/news/analyst-ratings/jefferies-reiterates-axsome-stock-buy-rating-on-pipeline-depth-93CH-4593769

0 · Reply

Georgejj Apr. 1 at 5:20 PM

$AXSM Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions https://finance.yahoo.com/sectors/healthcare/articles/axsome-therapeutics-acquires-selective-pde10a-110000091.html Good luck and GOD bless,

0 · Reply

Live2ride Apr. 1 at 4:53 PM

$AXSM sorry, that was the 50ma not the 200. Anyway, trading above it today so I'll take it. Be nice to close above it.

0 · Reply

quickaspeter Apr. 1 at 4:48 PM

$AXSM https://m.aktiencheck.de/news/Markt-Axsome_Therapeutics_Gains_Momentum_Ahead_of_Critical_FDA_Decision-19615985

0 · Reply

1golfer Apr. 1 at 3:24 PM

$AXSM looks like yahoo finance will not let me post, they keep removing them & all I was going to say is go baby go & yahoo finance message board police suck.

2 · Reply

LetsGetTheseCrumbs Apr. 1 at 3:05 PM

$AXSM in AXSM we trust 🇺🇸🫡

0 · Reply

11thestate Apr. 1 at 1:41 PM

$AXSM The $7,750,000 Axsome settlement is entering the final distribution phase. While the primary deadline has passed, the window for 'Late but Effective' claims is still open. If you held $AXSM between May 10, 2021– April 22, 2022, you must submit your trade history now to be included before the fund is locked and checks are mailed. We are assisting investors in submitting audited late claims to the court-appointed administrator. Don't let your share of the $7.75M go unclaimed, once the distribution starts, it's too late. Submit your late claim here: https://11th.com/cases/axsome-investor-settlement

0 · Reply

JulioD Apr. 1 at 11:50 AM

$AXSM here's the link to Takeda's schizophrenia trial of our newly acquired asset: https://clinicaltrials.gov/study/NCT02477020?tab=results

0 · Reply

Vakeshka Apr. 1 at 11:46 AM

$AXSM looks like Takeda discontinued further bslipodect clinical studies due to inadequate efficacy in schizophrenia. Thoughts on Axsome looking to progress this regardless into P3 for the same indication?

3 · Reply

badgermobile Apr. 1 at 11:34 AM

$AXSM the guy that bought 47 shares at 179 better learn how to use limit buys😀

1 · Reply

Market Cap	8.62B
Revenue (ttm)	638.50M
Net Income (ttm)	-183.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-28.69%
Debt to Equity Ratio	1.33

Volume	617,000
Avg Vol	584,372
Day's Range	N/A - N/A
Shares Out	51.15M
Stochastic %K	72%
Beta	0.48
Analysts	Strong Sell
Price Target	$223.40